XXII
22nd Century Group, Inc.
NASDAQ · Consumer Defensive · Tobacco · US
$1.79
+1.13%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.76
From 52W high−99.70%
Volume31909.00
Market cap$1.28M
P/E (TTM)—
P/S (TTM)0.1x
Div yield—
Key dataSep 18, 2026
Open
$1.76
From 52W high
−99.70%
Volume
31909.00
Market cap
$1.28M
ValuationView details →
P/E (Fwd)
0.1x
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
27.7
MomentumView details →
1D Return
+1.13%
YTD Return
−99.19%
SummaryUpdated Jun 1, 2026
22nd Century Group, Inc. (NASDAQ:XXII) is an agricultural biotechnology company founded in 1998 and headquartered in Buffalo, New York. The company went public in 2011 and has undergone significant strategic transformation over its history. Originally focused on developing genetically modified tobacco plants with altered nicotine content, the company expanded into hemp and cannabis biotechnology before recently divesting those operations to refocus exclusively on tobacco products. Today, 22nd Century operates as a pure-play tobacco company specializing in reduced nicotine cigarettes and contract manufacturing services for other tobacco companies.
Similar companies
Latest newsMore news →
Katherine Rouse-Bailey was appointed Vice President of Marketing at XXII, signaling a strategic shift toward brand-building and consumer engagement.29d ago22nd Century Group reported Q2 2026 net revenues of $2.9 million, down 29.9% year-over-year, with a net loss of $3.3 million and diluted EPS of -$15.6.39d ago